This is promotional content, intended for UK healthcare professionals only. This webpage has been initiated, funded and reviewed by the Bristol-Myers Squibb / Pfizer Alliance.

ELIQUIS (apixaban): an oral, direct factor Xa inhibitor indicated for:4
  • – Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)4
  • – Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults4
  • – Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery4
For both of us, efficacy and safety profiles matter

Prevention of stroke / systemic embolism in patients with NVAF

In patients with NVAF, ELIQUIS is the only factor Xa inhibitor to demonstrate both:1,5,6

  • Superiority on the prevention of stroke / systemic embolism vs. warfarin1
  • Superiority on the incidence of major bleeding vs. warfarin1

Choose ELIQUIS for superiority vs. warfarin in both clinical endpoints1

ELIQUIS is the only factor Xa inhibitor to offer both superior stroke protection and a superior major bleeding profile vs. warfarin1,5,6

Stroke / systemic embolism superior 21% RRR

Primary efficacy endpoint:
1.27% per year with ELIQUIS (n=212)
vs. 1.60% per year with warfarin (n=265) HR=0.79 (95% CI: 0.66–0.95);
p=0.01 for superiority1

In ARISTOTLE1†
Major bleeding superior 31% RRR

Primary safety endpoint:
2.13% per year with ELIQUIS (n=327)
vs. 3.09% per year with warfarin (n=462) HR=0.69 (95% CI: 0.60–0.80);
p<0.0011

Adapted from Granger et al. 2011.1

Additionally, ELIQUIS significantly reduced all-cause mortality vs. warfarin in patients with NVAF1

In ARISTOTLE1†

All-cause mortality 11% RRR vs warfarin

3.52% per year with ELIQUIS (n=603)
vs. 3.94% per year with warfarin (n=669)
HR=0.89 (95% CI: 0.80–0.998)
p=0.0471†

What are your anticoagulation treatment considerations?

NICE CG180 provides guidance on reassessing anticoagulation for people poorly controlled on VKA7

NICE CG182 suggests ELIQUIS as a consideration over warfarin in patients with a confirmed eGFR of 30–50 ml/min/1.73 m2 and NVAF8‡

ESC 2016 guidelines recommend NOACs, including ELIQUIS, over warfarin for most of your patients with NVAF

Patients with NVAF treated with ELIQUIS had fewer episodes of stroke or systemic embolism and fewer major bleeds vs. warfarin, with similar results across a broad range of subgroup populations and risk profiles1,10–14

Stroke risk1,10

Prior stroke / TIA1,11

Prior warfarin experience1,12

Renal function1,13#

Subgroups:
CrCl ≤50 ml/min
>50–80 ml/min
>80 ml/min

Age1,14

Subgroups:
<65 years
65 to <75 years
≥75 years

Patients with severe renal insufficiency (CrCl <25 ml/min) were excluded from ARISTOTLE. ELIQUIS is not recommended for patients with CrCl <15 ml/min or in patients undergoing dialysis.1,4 Please refer to the ELIQUIS Summary of Product Characteristics for full dose recommendations in patients with renal impairment.

ELIQUIS can benefit a broad range of patients with NVAF, with a broad range of risks10–14

EFFICACY AND SAFETY PROFILES MATTER:
Choose ELIQUIS for your patients with NVAF

For printable patient booklets, educational clinical resources and further details on ELIQUIS, visit www.ELIQUIS.co.uk